申请人:Astrazeneca AB
公开号:US06472435B1
公开(公告)日:2002-10-29
The invention concerns anti-tumor agents of formula (I), wherein each of R1, R2 and R3 has the meanings defined in the specification including hydrogen, (1-4C)alkyl, (3-4C)alkynyl and (1-4C)alkoxyl; each of R4 and R5 is (1-4C) alkyl; each of R6 and R7 is hydrogen or (1-4C)alkyl; X is N-(1-4C)alkylimino, N-(3-4C)alkenylimino, or (3-4C)alkynylimino; m is 1 or 2 and each R8 is as defined in the specification; each Y′ and Y2 is halogen, (1-4C)alkanesulphonyloxy, benzensulphonyloxy or phenyl-(1-4C)alkanesulfonyloxy; or a pharmaceutical acceptable salt thereof; provided that at least one of R1, R2 and R3 is other than hydrogen; a process for their preparation, pharmaceutical composition containing them and their use for producing an anti-proliferative effect in a warm-blooded animal.
本发明涉及式(I)的抗肿瘤剂,其中R1,R2和R3中的每一个具有规范中定义的含义,包括氢,(1-4C)烷基,(3-4C)炔基和(1-4C)烷氧基; R4和R5中的每一个是(1-4C)烷基; R6和R7中的每一个是氢或(1-4C)烷基; X是N-(1-4C)烷基亚胺基,N-(3-4C)烯基亚胺基或(3-4C)炔基亚胺基; m为1或2,每个R8如规范中所定义; 每个Y′和Y2是卤素,(1-4C)烷磺酰氧基,苯基磺酰氧基或苯基-(1-4C)烷基磺酰氧基; 或其药物可接受的盐; 前提是至少有一个R1,R2和R3不是氢; 它们的制备方法,含有它们的药物组合物以及它们用于在温血动物中产生抗增殖作用的用途。